Hla Class I Restriction
Hla Class I Restriction - Related Videos
08:07
Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
0 Views •
Cited by 2 •
2017
Mismatches in human leukocyte antigen (HLA) sequences between organ donor and recipient pairs are the major cause of antibody-mediated rejection in organ transplantation. Here we present the use of custom antigen arrays that are based on individual donors' HLA sequences to probe anti-donor HLA alloantibodies in organ recipients.
09:45
Restriction Enzyme Digests
0 Views •
2023
Restriction enzymes or endonucleases recognize and cut DNA at a specific sequence. These enzymes occur naturally in bacteria as a defense against bacteriophages - viruses that infect bacteria. Bacterial restriction enzymes cut the invading bacteriophage DNA while leaving the bacterial genomic DNA unharmed due to addition of methyl groups. This video explains the basic principles of restriction enzymes including: how restriction enzymes are named and the types of recognition sites and...
03:15
A Peptide Array-Based Detection of Anti-donor HLA Alloantibodies in Organ Recipients
0 Views •
2025
This video demonstrates an assay to detect anti-donor HLA alloantibodies in organ recipients. A peptide array is synthesized to represent potential epitopes for antibody-mediated organ rejection. The array is incubated with the recipient's serum, containing alloantibodies that bind to their target epitopes. Antibody binding is detected using chemiluminescence to identify donor-specific HLA epitopes that incite alloantibody reactivity.
09:37
Screening Foodstuffs for Class 1 Integrons and Gene Cassettes
0 Views •
Cited by 13 •
2015
This protocol describes the detection of class 1 integrons and their associated gene cassettes in foodstuffs.
10:37
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
0 Views •
Cited by 2 •
2021
Based on a hepatitis B virus (HBV)-derived peptide matrix, HBV-specific CD4 T-cell responses could be evaluated in parallel with identification of HBV-specific CD4 T-cell epitopes.
FAQs
Intracellular protein origin determines which peptides enter the surveillance pathway, but recognition also depends on molecular assembly. HLA-A, HLA-B, or HLA-C binds a peptide and associates with β2-microglobulin before the complex reaches the cell surface. A CD8+ T-cell receptor therefore evaluates a molecular display unit rather than an unconstrained peptide, linking antigen identity to HLA context.
Peptide identity alone does not determine whether a CD8+ T cell responds. The receptor must detect the peptide in a compatible HLA class I molecule, so the same antigenic information is interpreted through a particular human HLA context. This requirement gives immune surveillance specificity: recognition of a foreign or abnormal peptide can lead to destruction of the presenting cell.
These three HLA class I groups are the named molecules that display intracellularly derived peptides for CD8+ T-cell inspection. Their importance is practical as well as mechanistic: a T cell’s response depends on presentation by a compatible HLA molecule. Consequently, studies of immune recognition and transplant compatibility must consider which HLA class I context carries the peptide.
Viral infection studies can use this principle to connect infected-cell antigen display with CD8+ T-cell action. The relevant question is whether a foreign viral peptide appears in the appropriate HLA class I context and is recognized by the receptor. The resulting response provides a framework for understanding how adaptive immune surveillance may identify and eliminate infected cells.
Transplant research must account for HLA compatibility because CD8+ T-cell recognition is restricted to particular human HLA class I contexts. Differences in HLA-A, HLA-B, or HLA-C can therefore matter when interpreting how cells are inspected by T cells. The principle supplies an immunological basis for considering HLA compatibility as part of transplantation rather than treating antigen recognition as context-independent.
It identifies a design and interpretation constraint: candidate immune targets must be considered as peptides presented by HLA class I molecules, not as isolated protein sequences. In vaccine research, this frames how foreign antigenic information may be inspected by CD8+ T cells. In cancer immunotherapy, the same framework applies to abnormal cellular peptides and their potential to trigger targeted cell destruction.